Pradaxa (dabigatran) approved as alternative to warfarin for reducing atrial fibrillation stroke risk

The long-awaited alternative to Coumadin (warfarin) has just been approved by the US FDA. The FDA just approved Pradaxa (dabigatran) for use by those with atrial fibrillation for preventing afib-related strokes.

The FDA based approval on results of the RE-LY trial, which saw patients on Pradaxa having fewer strokes than those on warfarin. And Pradaxa doesn’t require the monitoring nor the restrictive diet that warfarin does.

Learn more at:

FDA Approves Pradaxa as Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation